Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. - Wikidata - wikimedia - TriplyDB

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.

http://www.wikidata.org/entity/Q36884023

about

Pharmacogenomics of human P450 oxidoreductase Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6 Concomitant mutations in the P450 oxidoreductase and androgen receptor genes presenting with 46,XY disordered sex development and androgenization at adrenarche.Suppression of cytochrome p450 reductase enhances long-term hematopoietic stem cell repopulation efficiency in mice.Effects of genetic factors on the pharmacokinetics and pharmacodynamics of amlodipine in primary hypertensive patients Genetic variations in NADPH-CYP450 oxidoreductase in a Czech Slavic cohort.NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology.Cytochrome P450 oxidoreductase deficiency caused by R457H mutation in POR gene in Chinese: case report and literature review.Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype?Effect of the P450 oxidoreductase 28 polymorphism on the pharmacokinetics of tacrolimus in Chinese healthy male volunteers.POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.Direct observation of multiple conformational states in Cytochrome P450 oxidoreductase and their modulation by membrane environment and ionic strength

P2860

Q26998463-369E7F7C-5F40-4D1F-A424-E8D4A99E7A6C Q28484196-C54C19AF-8ED9-4004-B02D-381429A47675 Q34766752-2C0A19CE-40C0-49A8-87C3-C5243B9F4BE9 Q34904803-33AE801F-4099-40D3-B1BD-36FBDD4BEB16 Q35662487-0E261605-8227-45D6-9FB3-4D9017FB07BE Q36326565-79D31B04-6BAA-45C4-896E-5CFB54B84A0A Q36497649-719EF6DB-8B5B-4AE3-B2E1-3B65248B584F Q37698004-99528812-FDE3-4F04-B54E-055223219896 Q43188221-A1D66C05-28F9-4562-B016-53CDB4AE79B5 Q44556926-24B91EC4-B421-4523-B6B6-32E20C538CED Q53665083-CB82CC18-3106-4A66-845E-1BEC61549F93 Q55112848-B9113ACF-4BA7-4A6D-9E38-BEF9AEF1C4D5

P2860

Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.

http://www.wikidata.org/entity/Q36884023

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Clinical, structural and funct ...... man NADPH P450 oxidoreductase.

@en

type

label

Clinical, structural and funct ...... man NADPH P450 oxidoreductase.

@en

prefLabel

Clinical, structural and funct ...... man NADPH P450 oxidoreductase.

@en

P1433

Q36884023-D3A2CDE6-901E-437F-8271-0EBA0A4F228D

P1476

Q36884023-867F22CE-B9DE-4330-8B97-6E0DE2767EF2

P2093

Q36884023-1500FE5B-324B-4F33-9717-D89AEBB78DD0

Q36884023-CD98A42E-069E-42F5-B5A0-28E3FC0F3698

P2860

Q36884023-0156DFDB-C91D-4543-81E0-821527B554D4

Q36884023-1E9A4968-D11D-42A3-9D74-A83DD53F3F22

Q36884023-22403688-38F5-4BE3-93DD-63DBC7120C4B

Q36884023-25945671-EAD2-4D9B-B9FB-E198AEA3DD3D

Q36884023-2C2969FC-D6EC-4EA5-A95C-4110454BEA06

Q36884023-30476E6F-4BCF-47B8-ABDC-2D0BA6870A6E

Q36884023-3144323F-4574-4DC1-8680-443537177748

Q36884023-38CD80A6-2DAE-4E6F-8B57-3527061E4B07

Q36884023-39903FE0-F443-4314-AF2D-06C10C1A6592

Q36884023-3E198B77-E24D-42CB-A852-4C220DDCD400

P304

Q36884023-96823C67-FAD5-483A-A605-FCC0FA4DE2C3

P31

Q36884023-6CF3AB17-647F-4828-A774-7B95E5396E07

P356

Q36884023-1098C667-5961-4C90-A172-D00996B2FA95

P433

Q36884023-FFF80B40-CD4B-4034-A190-3036D8264781

P478

Q36884023-F74982B7-1E21-4E03-BA5B-EE8BA9DA78AE

P50

Q36884023-34675887-6947-45E8-81FF-15F94ADF066A

P577

Q36884023-215A7821-B322-4938-BA95-51ABFE5C99B2

P698

Q36884023-EF676EE7-A94D-4F11-BD84-04BDA28F6934

P356

J.1472-8206.2007.00520.X

P1433

Fundamental and Clinical Pharmacology

P1476

Clinical, structural and funct ...... man NADPH P450 oxidoreductase.

@en

P2093

Catherine Nicolo

http://www.w3.org/2001/XMLSchema#string

Christa E Flück

http://www.w3.org/2001/XMLSchema#string

P2860

Structural and functional analysis of NADPH-cytochrome P-450 reductase from human liver: complete sequence of human enzyme and NADPH-binding sites

Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis

Three-dimensional structure of NADPH-cytochrome P450 reductase: prototype for FMN- and FAD-containing enzymes

NADPH-cytochrome P450 oxidoreductase. Structural basis for hydride and electron transfer

Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase

Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase

Protein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17

Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome

Kinetics of ferric cytochrome P450 reduction by NADPH-cytochrome P450 reductase: rapid reduction in the absence of substrate and variations among cytochrome P450 systems

Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study

P304

399-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1472-8206.2007.00520.X

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17635179

http://www.w3.org/2001/XMLSchema#string